The Division of Mental Health and Addiction Services (DMHAS) administers a system of care that consistently offers clients the means to seek and sustain recovery.
The DMHAS promotes evidence-based practices that include Medication-Assisted Treatment (MAT) in the management of substance use disorders. The U.S. Department of Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA) defines MAT as the use of medications, in combination with counseling and behavioral therapies, to provide a whole-patient approach to the treatment of substance use disorders. MAT is clinically driven with a focus on individualized patient care. Research continues to demonstrate medication, along with behavioral therapies, results in successful outcomes.
The FDA has approved certain medications for the treatment of substance use disorders. For alcohol use disorder, the medications include: Naltrexone, Disulfiram and Acamprosate Calcium. The current medications approved for the treatment of opioid use disorders are: Methadone, Buprenorphine and Naltrexone. For more information on this medications: http://dpt.samhsa.gov/medications/medsindex.aspx
The DMHAS licenses numerous treatment programs that serve consumers that want more information or are interested in accessing MAT for their treatment. Licensed treatment programs are listed on this site at
http://njsams.rutgers.edu/dastxdirectory/txdirmain.htm. For information regarding treatment programs and funding opportunities call the N.J. Addictions Hotline at 2-1-1
For information regarding the Medication Assisted Treatment Initiative (MATI), please call (609) 292-6735.
For Information regarding the Vivitrol Enhancement in the DMHAS Networks, please call (609) 292-8186.
For information regarding the Driving Under the Influence Vivitrol Pilot, please call (609) 292-8186.